These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24355028)

  • 1. Lyme disease vaccination: safety first.
    Stricker RB; Johnson L
    Lancet Infect Dis; 2014 Jan; 14(1):12. PubMed ID: 24355028
    [No Abstract]   [Full Text] [Related]  

  • 2. Lyme disease vaccination: safety first - authors' reply.
    Barrett PN; Crowe BA; Wressnigg N; Portsmouth D; Aichinger G
    Lancet Infect Dis; 2014 Jan; 14(1):12-13. PubMed ID: 24355029
    [No Abstract]   [Full Text] [Related]  

  • 3. Lyme disease vaccination: are we ready to try again?
    Lantos PM
    Lancet Infect Dis; 2013 Aug; 13(8):643-4. PubMed ID: 23665340
    [No Abstract]   [Full Text] [Related]  

  • 4. Lyme disease vaccination: safety first - author's reply.
    Lantos PM
    Lancet Infect Dis; 2014 Jan; 14(1):13. PubMed ID: 24355030
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
    Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
    Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
    Zhao H; Bao FF; Liu A
    J Infect Dev Ctries; 2017 Jan; 11(1):1-9. PubMed ID: 28141584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lyme vaccine demonized by advocacy groups.
    McSweegan E
    Nature; 2006 Mar; 440(7082):278. PubMed ID: 16541048
    [No Abstract]   [Full Text] [Related]  

  • 8. The need for a new vaccine against lyme borreliosis.
    Barrett PN; Portsmouth D
    Expert Rev Vaccines; 2013 Feb; 12(2):101-3. PubMed ID: 23414400
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
    Sikand VK; Halsey N; Krause PJ; Sood SK; Geller R; Van Hoecke C; Buscarino C; Parenti D;
    Pediatrics; 2001 Jul; 108(1):123-8. PubMed ID: 11433064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outer surface protein A and arthritis in hamsters.
    Parenti DL
    Infect Immun; 2000 Dec; 68(12):7212-3. PubMed ID: 11203324
    [No Abstract]   [Full Text] [Related]  

  • 11. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
    Wressnigg N; Barrett PN; Pöllabauer EM; O'Rourke M; Portsmouth D; Schwendinger MG; Crowe BA; Livey I; Dvorak T; Schmitt B; Zeitlinger M; Kollaritsch H; Esen M; Kremsner PG; Jelinek T; Aschoff R; Weisser R; Naudts IF; Aichinger G
    Clin Vaccine Immunol; 2014 Nov; 21(11):1490-9. PubMed ID: 25185574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Need for a New Lyme Disease Vaccine.
    Plotkin SA
    N Engl J Med; 2016 Sep; 375(10):911-3. PubMed ID: 27602662
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies.
    Barrett PN; Portsmouth D
    Expert Rev Vaccines; 2013 Sep; 12(9):973-5. PubMed ID: 24053389
    [No Abstract]   [Full Text] [Related]  

  • 14. Arthritis following recombinant outer surface protein A vaccination for Lyme disease.
    Rosé CD; Fawcett PT; Gibney KM
    J Rheumatol; 2001 Nov; 28(11):2555-7. PubMed ID: 11708435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lyme disease: uphill struggle.
    Abbott A
    Nature; 2006 Feb; 439(7076):524-5. PubMed ID: 16452949
    [No Abstract]   [Full Text] [Related]  

  • 16. Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics.
    Šmit R; Postma MJ
    Expert Rev Vaccines; 2015; 14(12):1549-61. PubMed ID: 26414102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A brief history of OspA vaccines including their impact on diagnostic testing for Lyme disease.
    Wormser GP
    Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115572. PubMed ID: 34763193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
    Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
    J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
    O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
    Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.